市场调查报告书
商品编码
1467696
2024-2032 年按产品、系统类型、应用、最终用户(医院、学术和政府研究机构、製药和生物技术公司、合约研究组织)和地区分類的雷射捕获显微切割市场报告Laser Capture Microdissection Market Report by Product, System Type, Application, End User (Hospitals, Academic and Government Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations ), and Region 2024-2032 |
IMARC Group年,全球雷射捕获显微切割市场规模达到 1.483 亿美元。
雷射捕获显微切割 (LCM) 是一种使用雷射光束和直接显微可视化将细胞与其周围组织分离的高分辨率方法。它依靠紫外线 (UV)、红外线和免疫萤光雷射光束从组织、血液和精液样本中收穫纯净的富集细胞群。它可以准确区分正常细胞和异常细胞以研究亚细胞概况。它用于福马林固定、石蜡包埋、冷冻和细胞学标本,用于研究基因表现和检测癌症。此外,它还应用于学术和政府研究机构、製药和生物技术公司、聚合酶炼式反应 (PCR)、蛋白质组学以及医院的下一代和桑格测序。
生物科学研究实验室中分子分析的使用不断增加,以及医疗保健产业的不断扩大,是推动市场的关键因素之一。此外,由于LCM可以透过灵敏的分析技术对细胞群(例如霍奇金氏病和原位癌的恶性细胞)进行精确的体内检查,因此其在全球的销售量正在不断增长。此外,一些国家政府的医疗保健支出和研发 (R&D) 资金也有所增加。再加上法医科学和分子生物学中心对 LCM 以获得可解释的 DNA 图谱的需求不断增长,正在刺激市场成长。除此之外,LCM也用于建立特定病理病变和恶性肿瘤的遗传指纹,以识别新的诊断和预后标记。它还有助于提供肿瘤的个人化治疗,这对市场产生了积极影响。此外,主要市场参与者正在引入配备免疫萤光雷射二极体的增强型 LCM 技术,以改善生物标记发现和癌症化学预防,预计这将促进市场的成长。
The global laser capture microdissection market size reached US$ 148.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 329.3 Million by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032.
Laser capture microdissection (LCM) is a high-resolution method of isolating cells from their surrounding tissues using a laser beam and direct microscopic visualization. It relies on ultraviolet (UV), infrared, and immunofluorescence laser beams to harvest pure enriched cell populations from tissue, blood, and semen samples. It accurately differentiates between normal and abnormal cells to investigate subcellular profiles. It is used on formalin-fixed, paraffin wax-embedded, frozen, and cytologic specimens for studying gene expression and detecting cancer. In addition, it finds application in academic and government research institutes, pharmaceutical and biotechnology companies, polymerase chain reaction (PCR), proteomics, and hospitals for next-generation and sanger sequencing.
The growing utilization of molecular analysis in a bioscience research laboratory, along with the expanding healthcare industry, represents one of the key factors driving the market. Moreover, as LCM allows precise vivo examination of cell populations, such as malignant cells of Hodgkin's disease and carcinoma in situ with sensitive analytical techniques, its sales are rising across the globe. Additionally, there is an increase in healthcare expenditure and research and development (R&D) funding by governments of several countries. This, along with the escalating demand for LCM in forensic science and molecular biology centers to obtain interpretable DNA profiles, is stimulating the market growth. Besides this, LCM is utilized for establishing genetic fingerprints of specific pathological lesions and malignant neoplasms to identify new diagnostic and prognostic markers. It also helps provide individualized treatment of tumor, which is positively influencing the market. Furthermore, key market players are introducing enhanced LCM technologies equipped with immunofluorescence laser diodes for improved biomarker discovery and cancer chemoprevention, which is projected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global laser capture microdissection market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, system type, application and end user.
Instruments
Consumables
Software and Services
Ultraviolet LCM
Infrared LCM
Others
Research and Development
Diagnostics
Others
Hospitals
Academic and Government Research Institutes
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs)
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AnaPath Services GmbH (ST Pharm Co. Ltd), Bio-RAD Laboratories Inc., Caresbio Laboratory LLC, Carl Zeiss Meditec AG (Carl Zeiss AG), Epistem Ltd, Fluidigm Corporation, Gnome Diagnostics LLC, HUBNER Photonics, Leica Microsystems GmbH (Danaher Corporation), Molecular Machines & Industries, Thermo Fisher Scientific Inc. and VitroVivo Biotech.